Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610398820780
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees1
Next Earnings Date2/13/2020 (Estimated)
OptionableNot Optionable
Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions
What is Propanc Biopharma's stock symbol?
Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."
When is Propanc Biopharma's next earnings date?
Has Propanc Biopharma been receiving favorable news coverage?
Media headlines about PPCB stock have trended very negative on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Propanc Biopharma earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Propanc Biopharma.
Who are some of Propanc Biopharma's key competitors?
Some companies that are related to Propanc Biopharma include Anthera Pharmaceuticals (ANTH), Peak Pharmaceuticals (PKPH), Cotinga Pharmaceuticals (COTQF), Boston Therapeutics (BTHE), Achaogen (AKAOQ), Argos Therapeutics (ARGSQ), Respirerx Pharmaceuticals (RSPI), Targeted Medical Pharma (TRGM), Spotlight Innovation (STLT), Skinvisible (SKVI), Orexigen Therapeutics (OREXQ), Inspyr Therapeutics (NSPX), Immune Therapeutics (IMUN), Aeolus Pharmaceuticals (AOLS) and Affymax (AFFY).
What other stocks do shareholders of Propanc Biopharma own?
Who are Propanc Biopharma's key executives?
Propanc Biopharma's management team includes the folowing people:
- Mr. James Nathanielsz, Acting Chairman, CEO, CFO, Sec., Treasurer & Director (Age 45)
- Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 71)
- Prof. Klaus Kutz, Chief Medical Officer & Member of Scientific Advisory Board
How do I buy shares of Propanc Biopharma?
Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Propanc Biopharma's stock price today?
One share of PPCB stock can currently be purchased for approximately $0.20.
How big of a company is Propanc Biopharma?
What is Propanc Biopharma's official website?
How can I contact Propanc Biopharma?
Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610398820780 or via email at [email protected]
MarketBeat Community Rating for Propanc Biopharma (OTCMKTS PPCB)
MarketBeat's community ratings are surveys of what our community members think about Propanc Biopharma and other stocks. Vote "Outperform" if you believe PPCB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PPCB will underperform the S&P 500 over the long term. You may vote once every thirty days.
